Internet Explorer Alert

It appears you are using Internet Explorer as your web browser. Please note, Internet Explorer is no longer up-to-date and can cause problems in how this website functions
This site functions best using the latest versions of any of the following browsers: Edge, Firefox, Chrome, Opera, or Safari.
You can find the latest versions of these browsers at https://browsehappy.com

Advertisement Disclaimer
Donate
Donate

Neonatal Resuscitation Program (NRP)

Search  /  Neonatal Resuscitation Program (NRP)

 

About the NRP

The Neonatal Resuscitation Program® (NRP®) course conveys an evidence-based approach to care of the newborn at birth and facilitates e​ffective team-based care for healthcare professionals who care for newborns at the time of delivery. NRP utilizes a blended learning approach, which includes online testing, online case-based simulations, and hands-on case-based simulation/debriefing that focus on critical leadership, communication, and team-work skills.​​

Neonatal Resuscitation Program

0
Language

English

(116799)

Spanish

(3099)

AAP Categories

News Releases

(17081)

News Releases from the AAP

(752)

Committees Councils Sections

(751)

News Releases from Pediatrics

(574)

Bright Futures

(334)

AAP Experience

(9)

Showing 1 - 10 of 821 results.

Advanced Search Tips

0
Language

English

(116799)

Spanish

(3099)

AAP Categories

News Releases

(17081)

News Releases from the AAP

(752)

Committees Councils Sections

(751)

News Releases from Pediatrics

(574)

Bright Futures

(334)

AAP Experience

(9)

Atopic Dermatitis: Update On Skin-Directed Management: Clinical Report
Pediatrics ·Volume ·Number
May 19, 2025
Atopic dermatitis affects 20% to 25% of children and has significant impact on quality of life of patients and families. Recent studies of the pathogenesis of AD highlight the interplay between a defective skin barrier, immune dysfunction, and the cutaneous microbiome. Standard of care for AD treatment includes topical corticosteroids for active disease and moisturization to repair the barrier defect. Emerging treatments include dupilumab and Janus kinase (JAK) inhibitors. Reduction of triggers and proactive treatment with topical corticosteroids and/or topical calcineurin inhibitors can reduce flares. Treatment plans should be clear and as simple as poss...
EczemaTopical CorticosteroidPruritus
https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-071812/201952/Atopic-Dermatitis-Update-on-Skin-Directed
Use Of Chaperones For The Pediatric And Adolescent Encounter: Policy Statement
Pediatrics ·Volume ·Number
May 19, 2025
Pediatric inpatient and outpatient encounters often include examinations that may be perceived as intrusive or uncomfortable by patients because of examination of sensitive body areas. The presence of a chaperone during these examinations can serve to optimize the patient's sense of comfort and safety, as well as protecting the physician. Chaperones should usually be clinical staff members, although providing adequate staffing may not be feasible for many small practices. Thus, the decision to use a chaperone and the specific choice of chaperone should be made jointly by the patient, parent and clinician providing care, considering the wishes of all parties to the encounter. Certain situations, including telemedicine encounters, unaccompanied minors, patients with intellectual disability, those suffering from abuse, exploitation or trafficking and those who are otherwise unable to assent to care or participate in shared decision making require special consideration for sensitive examinations, with attention paid to principles of trauma-informed care. All outpatient practices and inpatient services should develop policies addressing the situations which might prompt the need for a chaperone, and...
Molecular Chaperones
https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-071810/201949/Use-of-Chaperones-for-the-Pediatric-and-Adolescent
Patent Ductus Arteriosus In Preterm Infants
Pediatrics ·Volume ·Number
April 28, 2025
Despite extensive research in basic science and in clinical settings with thousands of infants over decades, uncertainty and controversy persist regarding the significance, assessment, and management of the patent ductus arteriosus (PDA) in preterm infants, resulting in substantial variability in clinical approach. This clinical report aims to succinctly review the available evidence to guide evaluation and treatment of preterm infants with prolonged ductal patency. Delayed closure of the PDA is common in preterm infants, particularly at more extreme immaturity. Echocardiography is essential for confirming the presence of a PDA and assessing hemodynamic significance. Medical closure of a PDA using ibuprofen or acetaminophen is an option for a hemodynamically significant PDA (hsPDA). Recent data from multiple clinical trials indicate the lack of benefits of prophylactic or early (<2 weeks of age) medical closure of PDA as compared with expectant management, and they are, therefore, not recommended. There are insufficient data to support firm recommendations on management of infants with an hsPDA beyond 2 weeks of age as relative benefits and risks of expectant management with close monitoring, attempted pharmacologic closure, or procedural (transcatheter/surgical) closure have not been adequately defined. Many clinicians attempt medical closure of an hsPDA beyond 2 weeks of age. If the hsPDA persists despite medical therapy (or if medical therapy is contraindicated), such infants may be considered for either transcatheter closure or surgical ligation. In recent years, surgical closure of the PDA has become less frequent, and transcatheter closure is more common in many centers. Although there are known adverse effects of an hsPDA, there is a lack of evidence to...
EchocardiographyPatent Ductus ArteriosusIbuprofenLigationTranscatheter ClosureSurgical Closure TechniquesIndomethacin
https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-071425/201674/Patent-Ductus-Arteriosus-in-Preterm-Infants
2025 Recommendations For Preventive Pediatric Health Care: Policy Statement
Pediatrics ·Volume ·Number
April 21, 2025
The 2025 Recommendations for Preventive Pediatric Health Care (Periodicity Schedule) has been approved by the American Academy of Pediatrics (AAP). Each child and family is unique; therefore, these recommendations are designed for the care of children who are receiving nurturing parenting, have no manifestations of any important health problems, and are growing and developing in a satisfactory fashion. Developmental, psychosocial, and chronic disease issues for children and adolescents may require more frequent counseling and treatment visits separate from preventive care visits. Additional visits also may become necessary if circumstances suggest concerns. The AAP continues to emphasize the great importance of continuity of care in comprehensive health supervision and the need to avoid fragmentation of care.1To ensure that health care professionals have the most current recommendations, the Periodicity Schedule is not published in Pediatrics but is posted on the American Academy of Pediatrics website (www.aap.org/periodicityschedule). This webpage includes the most recent version of the Periodicity Schedule and the full set of footnotes. The Periodicity Schedule is reviewed and revised annually to reflect current evidence and recommendations. This review process did not identify sufficient evidence to support updates to the 2025 Periodicity Schedule. The approved 2025 Periodicity Schedule remains unchanged from the 2024 Periodicity Schedule.Robin M. Warner, MD, FAAP, ChairpersonCarolyn Cleary, MD, FAAPMona Doss Roberts, MD, FAAPElizabeth Hawse, MD, FAAPCailly Howell-McLean, MD, FAAPLisa M. Kafer, MD, FAAPSeth D. Kaplan, MD, FAAP - Section on Administration and Practice Management LiaisonTomitra Latimer, MD, FAAPRobert H. Wiskind, MD, FAAPJesse M. Hackell, MD, FAAP, ChairpersonYvette M. Almendarez, MD, FAAPPatricia E. Cantrell, MD, FAAPCarolyn Cleary, MD, FAAPElizabeth Hawse, MD, FAAPLisa M. Kafer, MD, FAAPSeth D....
Child Health
https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-071066/200933/2025-Recommendations-for-Preventive-Pediatric
Use Of Chaperones For The Pediatric And Adolescent Encounter: Policy Statement
Pediatrics ·Volume 155·Number 6
April 1, 2025
Pediatric inpatient and outpatient encounters often include examinations that may be perceived as intrusive or uncomfortable by patients because of examination of sensitive body areas. The presence of a chaperone during these examinations can serve to optimize the patient's sense of comfort and safety, as well as protecting the physician. Chaperones should usually be clinical staff members, although providing adequate staffing may not be feasible for many small practices. Thus, the decision to use a chaperone and the specific choice of chaperone should be made jointly by the patient, parent and clinician providing care, considering the wishes of all parties to the encounter. Certain situations, including telemedicine encounters, unaccompanied minors, patients with intellectual disability, those suffering from abuse, exploitation or trafficking and those who are otherwise unable to assent to care or participate in shared decision making require special consideration for sensitive examinations, with attention paid to principles of trauma-informed care. All outpatient practices and inpatient services should develop policies addressing the situations which might prompt the need for a chaperone, and...
Molecular Chaperones
https://publications.aap.org/pediatrics/article/155/6/e2025071810/201949/Use-of-Chaperones-for-the-Pediatric-and-Adolescent
2025 Recommendations For Preventive Pediatric Health Care: Policy Statement
Pediatrics ·Volume 155·Number 5
April 1, 2025
The 2025 Recommendations for Preventive Pediatric Health Care (Periodicity Schedule) has been approved by the American Academy of Pediatrics (AAP). Each child and family is unique; therefore, these recommendations are designed for the care of children who are receiving nurturing parenting, have no manifestations of any important health problems, and are growing and developing in a satisfactory fashion. Developmental, psychosocial, and chronic disease issues for children and adolescents may require more frequent counseling and treatment visits separate from preventive care visits. Additional visits also may become necessary if circumstances suggest concerns. The AAP continues to emphasize the great importance of continuity of care in comprehensive health supervision and the need to avoid fragmentation of care.1To ensure that health care professionals have the most current recommendations, the Periodicity Schedule is not published in Pediatrics but is posted on the American Academy of Pediatrics website (www.aap.org/periodicityschedule). This webpage includes the most recent version of the Periodicity Schedule and the full set of footnotes. The Periodicity Schedule is reviewed and revised annually to reflect current evidence and recommendations. This review process did not identify sufficient evidence to support updates to the 2025 Periodicity Schedule. The approved 2025 Periodicity Schedule remains unchanged from the 2024 Periodicity Schedule.Robin M. Warner, MD, FAAP, ChairpersonCarolyn Cleary, MD, FAAPMona Doss Roberts, MD, FAAPElizabeth Hawse, MD, FAAPCailly Howell-McLean, MD, FAAPLisa M. Kafer, MD, FAAPSeth D. Kaplan, MD, FAAP - Section on Administration and Practice Management LiaisonTomitra Latimer, MD, FAAPRobert H. Wiskind, MD, FAAPJesse M. Hackell, MD, FAAP, ChairpersonYvette M. Almendarez, MD, FAAPPatricia E. Cantrell, MD, FAAPCarolyn Cleary, MD, FAAPElizabeth Hawse, MD, FAAPLisa M. Kafer, MD, FAAPSeth D....
Ambulatory Care Services
https://publications.aap.org/pediatrics/article/155/5/e2025071066/200933/2025-Recommendations-for-Preventive-Pediatric
Atopic Dermatitis: Update On Skin-Directed Management: Clinical Report
Pediatrics ·Volume 155·Number 6
April 1, 2025
Atopic dermatitis affects 20% to 25% of children and has significant impact on quality of life of patients and families. Recent studies of the pathogenesis of AD highlight the interplay between a defective skin barrier, immune dysfunction, and the cutaneous microbiome. Standard of care for AD treatment includes topical corticosteroids for active disease and moisturization to repair the barrier defect. Emerging treatments include dupilumab and Janus kinase (JAK) inhibitors. Reduction of triggers and proactive treatment with topical corticosteroids and/or topical calcineurin inhibitors can reduce flares. Treatment plans should be clear and as simple as poss...
Atopic DermatitisSkinPrecipitating FactorsCalcineurin Inhibitors
https://publications.aap.org/pediatrics/article/155/6/e2025071812/201952/Atopic-Dermatitis-Update-on-Skin-Directed
Postnatal Cord Blood Sampling: Clinical Report
Pediatrics ·Volume 155·Number 6
April 1, 2025
Blood contained in the umbilical cord after placental separation originates from the infant and can be used for neonatal blood sampling and testing after birth. The most common indications for phlebotomy after birth include care processes for any infant admitted to the neonatal intensive care unit, early-onset sepsis evaluations, and congenital anomalies. Postnatal umbilical cord blood sampling (PCBS), rather than obtaining blood from the neonate, avoids significant neonatal blood loss at a critical time of extrauterine transition and prevents phlebotomy pain in infants without a catheter for blood drawing. Studies of PCBS in very low birth weight infants have demonstrated additional benefits including stable blood pressure, less need for vasopressors and erythrocyte transfusions in the first week, and a potentially decreased risk for intracranial hemorrhage.PCBS can be used for any full-term or preterm infant when the need for phlebotomy is known at or shorty after delivery. PCBS can be the first option and reliably used for complete blood cell counts, blood cultures, blood typing and crossmatching, newborn screening and metabolic tests, genetic testing, blood chemistries, and coagulation studies. Additionally, PCBS allows the collection of larger blood volumes for blood culture, thereby improving positivity rate. Finally, PCBS can be performed after delayed cord clamping or cord milking a...
Polychlorinated BiphenylsBlood CultureBlood Coagulation Tests
https://publications.aap.org/pediatrics/article/155/6/e2025071811/201956/Postnatal-Cord-Blood-Sampling-Clinical-Report
Postnatal Cord Blood Sampling: Clinical Report
Pediatrics ·Volume 155·Number 6
April 1, 2025
Blood contained in the umbilical cord after placental separation originates from the infant and can be used for neonatal blood sampling and testing after birth. The most common indications for phlebotomy after birth include care processes for any infant admitted to the neonatal intensive care unit, early-onset sepsis evaluations, and congenital anomalies. Postnatal umbilical cord blood sampling (PCBS), rather than obtaining blood from the neonate, avoids significant neonatal blood loss at a critical time of extrauterine transition and prevents phlebotomy pain in infants without a catheter for blood drawing. Studies of PCBS in very low birth weight infants have demonstrated additional benefits including stable blood pressure, less need for vasopressors and erythrocyte transfusions in the first week, and a potentially decreased risk for intracranial hemorrhage.PCBS can be used for any full-term or preterm infant when the need for phlebotomy is known at or shorty after delivery. PCBS can be the first option and reliably used for complete blood cell counts, blood cultures, blood typing and crossmatching, newborn screening and metabolic tests, genetic testing, blood chemistries, and coagulation studies. Additionally, PCBS allows the collection of larger blood volumes for blood culture, thereby improving positivity rate. Finally, PCBS can be performed after delayed cord clamping or cord milking a...
Polychlorinated BiphenylsBlood CultureBlood Coagulation Tests
https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2025-071811/201956/Postnatal-Cord-Blood-Sampling-Clinical-Report
Disclosure Of Adverse Events In Pediatrics: Policy Statement
Pediatrics ·Volume 155·Number 4
April 1, 2025
Disclosure of adverse events has become the expectation in medicine and is widely regarded as the appropriate path when medical errors occur. Although data are limited on adverse events in pediatrics, that they occur frequently is uncontested. Types and rates of errors vary depending on the care setting and patient population. Patients with complex medical conditions or from historically marginalized groups or minoritized communities likely suffer disparate health and safety outcomes. Systemic factors, including nonpunitive safety cultures and supportive environments within institutions, are essential to promoting disclosure. State laws protecting apologies from use in legal proceedings can also help to encourage open communication. Some states have adopted laws to advance disclosure, and governmental agencies provide materials encouraging open communication and early resolution after adverse events occur. Many programs emphasize the importance of supporting health care workers involved in adverse events. Shame, fear of professional and legal repercussions, and lack of training remain barriers to disclosure. Education for health care clinicians, support in health care settings, additional research...
Disclosure
https://publications.aap.org/pediatrics/article/155/4/e2025070880/201289/Disclosure-of-Adverse-Events-in-Pediatrics-Policy
1
2
3
4
5
6
...
83
1
2
3
4
...
83
Feedback Form